Product image of Mirabegron Eg (Mirabegron) supplied by GNH India

Mirabegron Eg

Active Ingredient:
Mirabegron
Origin:
EU

Mirabegron Eg (Mirabegron)

Mirabegron, the active ingredient in Mirabegron Eg, is a β3‑adrenergic receptor agonist presented as an oral tablet for oral use. It treats overactive bladder symptoms such as urgency, frequency and urge incontinence in adults.

GNH India supplies Mirabegron Eg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Eurogenerics N.V./S.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Mirabegron is a β3‑adrenergic receptor agonist used in the management of overactive bladder.

  • Overactive bladder: improves bladder capacity and reduces urgency episodes.
  • Urinary urgency: decreases the frequency of sudden urges to void.
  • Urge urinary incontinence: lowers the number of involuntary leakage episodes.

How It Works

  • Mirabegron selectively activates β3‑adrenergic receptors in the detrusor smooth muscle of the bladder. This activation triggers a cascade that relaxes the muscle, increases functional bladder capacity, and diminishes involuntary contractions, thereby reducing urgency, frequency, and urge incontinence in patients with overactive bladder.

Side Effects

Adverse reactions may occur with Mirabegron use.

Common Side Effects

  • Hypertension: elevated blood pressure readings.
  • Nasopharyngitis: mild upper‑respiratory tract infection symptoms.
  • Headache: intermittent mild to moderate pain.
  • Constipation: reduced bowel movements.
  • Dry mouth: decreased salivation.

Serious or Rare Side Effects

  • Urinary retention: difficulty emptying the bladder.
  • Severe hypertension: markedly high blood pressure requiring medical attention.
  • Tachycardia: rapid heart rate.
  • Angioedema: swelling of face, lips, or throat.
  • Allergic reactions: rash, itching, or anaphylaxis.

Precautions & Warnings

Before prescribing Mirabegron, clinicians should consider several safety measures.

  • Assess cardiovascular status: monitor blood pressure regularly.
  • Evaluate renal function: adjust use in patients with impaired kidneys.
  • Review concomitant medications: avoid strong CYP2D6 inhibitors.
  • Use caution in uncontrolled hypertension: consider alternative therapy.
  • Monitor for urinary retention: advise patients to report difficulty voiding.
  • Store at below 25°C: keep in the original pack, protect from moisture.

Avoid Interactions

Mirabegron may interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid)

  • Strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine): may increase Mirabegron exposure.
  • Co‑administration with other β3‑adrenergic agonists: risk of additive cardiovascular effects.

Moderate Interactions (Monitor Closely):\n- CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may modestly raise plasma levels.

  • Diuretics: combined effect on blood pressure should be observed.
  • NSAIDs: may enhance risk of hypertension.

Frequently Asked Questions

Mirabegron Eg is indicated for the management of overactive bladder, including symptoms such as urinary urgency, increased frequency, and urge urinary incontinence in adult patients.

Mirabegron selectively stimulates β3‑adrenergic receptors in the bladder’s detrusor muscle, causing relaxation of the muscle, increasing bladder capacity, and reducing involuntary contractions that lead to urgency and incontinence.

The appropriate dose of Mirabegron Eg is determined by the prescribing healthcare professional based on the patient’s clinical condition, renal function, and any concomitant medications.

The safety of Mirabegron in pregnancy and lactation has not been established. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and under medical supervision.

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Unlike anticholinergics, which block muscarinic receptors, Mirabegron activates β3‑adrenergic receptors, offering an alternative mechanism that may be better tolerated in patients who experience dry mouth or constipation with anticholinergic therapy.

Mirabegron Eg should be stored at temperatures below 25 °C, in the original packaging, and protected from moisture and direct sunlight to maintain product stability.

Mirabegron Eg is taken orally, usually as a whole tablet with or without food, as directed by the prescribing clinician.

Serious risks include significant hypertension, urinary retention, tachycardia, and rare allergic reactions such as angioedema. Patients should seek immediate medical attention if they experience these symptoms.

Mirabegron is contraindicated in patients with uncontrolled hypertension, severe renal impairment without dose adjustment, or known hypersensitivity to Mirabegron or any of its excipients.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Mirabegron

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT